Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
RXRA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of RXRA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGDR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PTGDR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
REEP4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of REEP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
REEP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of REEP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RARG Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of RARG sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RARA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of RARA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PGR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PGR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PNRC2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PNRC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PNMA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PNMA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PPARA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PPARA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PAQR4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PAQR4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NRIP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of NRIP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
186
187
188
189
190
>>
2926
>